Upstream Bio Inc

NASDAQ:UPBUnited States

Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist in development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin. The Company has advanced this highly potent monoclonal antibody into separate Phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) and plans to initiate development of chronic obstructive pulmonary disease (COPD).

Contact Information

Headquarters

890 Winter Street, Suite 200WALTHAM, MA, United States 02451

Phone

781-208-2466

Fax

302-636-5454

Executives

Independent Chairman of the Board

Ronald Renaud

Chief Executive Officer, Director

E. Rand Sutherland

Chief Financial Officer, Chief Operating Officer

Michael Gray

Chief Medical Officer, Head - Research and Development

Aaron Deykin

Chief Business Officer

Adam Houghton